Denne side blev automatisk oversat, og nøjagtigheden af oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

12. juli 2016 opdateret af: Alliance for Clinical Trials in Oncology

Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy

RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of breast cancer in the future.

PURPOSE: This clinical trial is studying changes in breast density and blood hormone levels in postmenopausal women receiving anastrozole or exemestane for breast cancer.

Studieoversigt

Status

Afsluttet

Betingelser

Brystkræft

Intervention / Behandling

Detaljeret beskrivelse

OBJECTIVES:

To assess the changes in percent breast density (in response to 1 year of aromatase inhibitor therapy) from levels prior to the initiation of treatment.
To assess the changes in dense area (in response to 1 year of aromatase inhibitor therapy) from levels prior to the initiation of treatment.
To examine whether changes in percent breast density (in response to 1 year of aromatase inhibitor therapy) from pre-treatment levels correlate with changes in plasma hormone levels (estrone, estrone-sulfate, estradiol, and SHBG) and drug levels (anastrozole or exemestane) over the same time period.
To examine whether changes in dense area (in response to 1 year of aromatase inhibitor therapy) from pre-treatment mammogram correlate with changes in plasma hormone levels (estrone, estrone-sulfate, estradiol, and SHBG) and drug levels (anastrozole or exemestane) over the same time period.
To assess whether women with high pre-treatment percent density (upper tertile) experience greater decreases in percent breast density after 1 year of aromatase inhibitor therapy than women with low pre-treatment percent density (lower tertile).
To assess whether women with high pre-treatment dense area (upper tertile) experience greater decreases in dense area after 1 year of aromatase inhibitor therapy than women with low pre-treatment dense area (lower tertile).
To examine the associations of haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway identified through the Mayo Clinic and Indiana University Pharmacogenomics Research Network Projects, with changes in percent and area density, plasma hormone levels, and drug levels after 1 year of aromatase inhibitor therapy.

OUTLINE: This is a multicenter study.

Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.

Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

140

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Forenede Stater
- Georgia
  - Augusta, Georgia, Forenede Stater, 30912
    - MBCCOP - Medical College of Georgia Cancer Center
- Illinois
  - Aurora, Illinois, Forenede Stater, 60504
    - Rush-Copley Cancer Care Center
  - Bloomington, Illinois, Forenede Stater, 61701
    - St. Joseph Medical Center
  - Canton, Illinois, Forenede Stater, 61520
    - Graham Hospital
  - Carthage, Illinois, Forenede Stater, 62321
    - Memorial Hospital
  - Effingham, Illinois, Forenede Stater, 62401
    - St. Anthony's Memorial Hospital
  - Eureka, Illinois, Forenede Stater, 61530
    - Eureka Community Hospital
  - Galesburg, Illinois, Forenede Stater, 61401
    - Galesburg Cottage Hospital
  - Galesburg, Illinois, Forenede Stater, 61401
    - Galesburg Clinic, PC
  - Havana, Illinois, Forenede Stater, 62644
    - Mason District Hospital
  - Hopedale, Illinois, Forenede Stater, 61747
    - Hopedale Medical Complex
  - Joliet, Illinois, Forenede Stater, 60435
    - Joliet Oncology-Hematology Associates, Limited - West
  - Macomb, Illinois, Forenede Stater, 61455
    - Mcdonough District Hospital
  - Moline, Illinois, Forenede Stater, 61265
  - Moline, Illinois, Forenede Stater, 61265
    - Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
  - Normal, Illinois, Forenede Stater, 61761
    - Bromenn Regional Medical Center
  - Normal, Illinois, Forenede Stater, 61761
    - Community Cancer Center
  - Ottawa, Illinois, Forenede Stater, 61350
    - Community Hospital of Ottawa
  - Ottawa, Illinois, Forenede Stater, 61350
    - Oncology Hematology Associates of Central Illinois, PC - Ottawa
  - Pekin, Illinois, Forenede Stater, 61554
    - Cancer Treatment Center at Pekin Hospital
  - Peoria, Illinois, Forenede Stater, 61636
    - Methodist Medical Center of Illinois
  - Peoria, Illinois, Forenede Stater, 61614
    - Proctor Hospital
  - Peoria, Illinois, Forenede Stater, 61637
    - OSF St. Francis Medical Center
  - Peoria, Illinois, Forenede Stater, 61615
    - CCOP - Illinois Oncology Research Association
  - Peoria, Illinois, Forenede Stater, 61615
    - Oncology Hematology Associates of Central Illinois, PC - Peoria
  - Peru, Illinois, Forenede Stater, 61354
    - Illinois Valley Community Hospital
  - Princeton, Illinois, Forenede Stater, 61356
    - Perry Memorial Hospital
  - Spring Valley, Illinois, Forenede Stater, 61362
    - St. Margaret's Hospital
  - Urbana, Illinois, Forenede Stater, 61801
    - Carle Cancer Center at Carle Foundation Hospital
  - Urbana, Illinois, Forenede Stater, 61801
    - CCOP - Carle Cancer Center
- Indiana
  - Beech Grove, Indiana, Forenede Stater, 46107
    - St. Francis Hospital and Health Centers - Beech Grove Campus
  - Michigan City, Indiana, Forenede Stater, 46360
    - Saint Anthony Memorial Health Centers
  - Richmond, Indiana, Forenede Stater, 47374
    - Reid Hospital & Health Care Services
- Iowa
  - Ames, Iowa, Forenede Stater, 50010
    - McFarland Clinic, PC
  - Bettendorf, Iowa, Forenede Stater, 52722
  - Des Moines, Iowa, Forenede Stater, 50309
    - CCOP - Iowa Oncology Research Association
  - Des Moines, Iowa, Forenede Stater, 50309
    - John Stoddard Cancer Center at Iowa Methodist Medical Center
  - Des Moines, Iowa, Forenede Stater, 50309
    - Medical Oncology and Hematology Associates at John Stoddard Cancer Center
  - Des Moines, Iowa, Forenede Stater, 50314
    - Medical Oncology and Hematology Associates at Mercy Cancer Center
  - Des Moines, Iowa, Forenede Stater, 50314
    - Mercy Cancer Center at Mercy Medical Center - Des Moines
  - Des Moines, Iowa, Forenede Stater, 50316
    - John Stoddard Cancer Center at Iowa Lutheran Hospital
  - Des Moines, Iowa, Forenede Stater, 50307
    - Mercy Capitol Hospital
  - Mason City, Iowa, Forenede Stater, 50401
    - Mercy Cancer Center at Mercy Medical Center - North Iowa
  - Sioux City, Iowa, Forenede Stater, 51101
    - Siouxland Hematology-Oncology Associates, LLP
  - Sioux City, Iowa, Forenede Stater, 51104
    - St. Luke's Regional Medical Center
  - Sioux City, Iowa, Forenede Stater, 51104
    - Mercy Medical Center - Sioux City
- Kansas
  - Chanute, Kansas, Forenede Stater, 66720
    - Cancer Center of Kansas, PA - Chanute
  - Dodge City, Kansas, Forenede Stater, 67801
    - Cancer Center of Kansas, PA - Dodge City
  - El Dorado, Kansas, Forenede Stater, 67042
    - Cancer Center of Kansas, PA - El Dorado
  - Kingman, Kansas, Forenede Stater, 67068
    - Cancer Center of Kansas, PA - Kingman
  - Liberal, Kansas, Forenede Stater, 67901
    - Southwest Medical Center
  - Newton, Kansas, Forenede Stater, 67114
    - Cancer Center of Kansas, PA - Newton
  - Parsons, Kansas, Forenede Stater, 67357
    - Cancer Center of Kansas, PA - Parsons
  - Pratt, Kansas, Forenede Stater, 67124
    - Cancer Center of Kansas, PA - Pratt
  - Salina, Kansas, Forenede Stater, 67042
    - Cancer Center of Kansas, PA - Salina
  - Wellington, Kansas, Forenede Stater, 67152
    - Cancer Center of Kansas, PA - Wellington
  - Wichita, Kansas, Forenede Stater, 67214
    - Wesley Medical Center
  - Wichita, Kansas, Forenede Stater, 67208
    - Cancer Center of Kansas, PA - Medical Arts Tower
  - Wichita, Kansas, Forenede Stater, 67214
    - Cancer Center of Kansas, PA - Wichita
  - Wichita, Kansas, Forenede Stater, 67214
    - CCOP - Wichita
  - Wichita, Kansas, Forenede Stater, 67214
    - Via Christi Cancer Center at Via Christi Regional Medical Center
  - Wichita, Kansas, Forenede Stater, 67208
    - Associates in Womens Health, PA - North Review
  - Winfield, Kansas, Forenede Stater, 67156
    - Cancer Center of Kansas, PA - Winfield
- Michigan
  - Adrian, Michigan, Forenede Stater, 49221
    - Hickman Cancer Center at Bixby Medical Center
  - Lambertville, Michigan, Forenede Stater, 48144
    - Haematology-Oncology Associates of Ohio and Michigan, PC
  - Monroe, Michigan, Forenede Stater, 48162
    - Community Cancer Center of Monroe
  - Monroe, Michigan, Forenede Stater, 48162
    - Mercy Memorial Hospital - Monroe
- Minnesota
  - Bemidji, Minnesota, Forenede Stater, 56601
    - MeritCare Bemidji
  - Burnsville, Minnesota, Forenede Stater, 55337
    - Fairview Ridges Hospital
  - Coon Rapids, Minnesota, Forenede Stater, 55433
    - Mercy and Unity Cancer Center at Mercy Hospital
  - Duluth, Minnesota, Forenede Stater, 55805
    - CCOP - Duluth
  - Duluth, Minnesota, Forenede Stater, 55805-1983
    - Duluth Clinic Cancer Center - Duluth
  - Duluth, Minnesota, Forenede Stater, 55805
    - Miller - Dwan Medical Center
  - Edina, Minnesota, Forenede Stater, 55435
    - Fairview Southdale Hospital
  - Fridley, Minnesota, Forenede Stater, 55432
    - Mercy and Unity Cancer Center at Unity Hospital
  - Hutchinson, Minnesota, Forenede Stater, 55350
    - Hutchinson Area Health Care
  - Lichfield, Minnesota, Forenede Stater, 55355
    - Meeker County Memorial Hospital
  - Mankato, Minnesota, Forenede Stater, 56002
    - Immanuel St. Joseph's
  - Maplewood, Minnesota, Forenede Stater, 55109
    - Minnesota Oncology Hematology, PA - Maplewood
  - Maplewood, Minnesota, Forenede Stater, 55109
    - HealthEast Cancer Care at St. John's Hospital
  - Minneapolis, Minnesota, Forenede Stater, 55407
    - Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
  - Minneapolis, Minnesota, Forenede Stater, 55415
    - Hennepin County Medical Center - Minneapolis
  - Robbinsdale, Minnesota, Forenede Stater, 55422-2900
    - Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
  - Saint Louis Park, Minnesota, Forenede Stater, 55416
    - CCOP - Metro-Minnesota
  - Saint Louis Park, Minnesota, Forenede Stater, 55416
    - Park Nicollet Cancer Center
  - Saint Paul, Minnesota, Forenede Stater, 55102
    - United Hospital
  - Saint Paul, Minnesota, Forenede Stater, 55102
    - HealthEast Cancer Care at St. Joseph's Hospital
  - Shakopee, Minnesota, Forenede Stater, 55379
    - St. Francis Cancer Center at St. Francis Medical Center
  - St. Paul, Minnesota, Forenede Stater, 55101
    - Regions Hospital Cancer Care Center
  - Waconia, Minnesota, Forenede Stater, 55387
    - Ridgeview Medical Center
  - Woodbury, Minnesota, Forenede Stater, 55125
    - Minnesota Oncology Hematology, PA - Woodbury
  - Woodbury, Minnesota, Forenede Stater, 55125
    - HealthEast Cancer Care at Woodwinds Health Campus
- Missouri
  - Saint Louis, Missouri, Forenede Stater, 63131
    - Missouri Baptist Cancer Center
  - Saint Louis, Missouri, Forenede Stater, 63141
    - Arch Medical Services, Incorporated at Center for Cancer Care and Research
- Montana
  - Billings, Montana, Forenede Stater, 59101
    - CCOP - Montana Cancer Consortium
  - Billings, Montana, Forenede Stater, 59101
    - Hematology-Oncology Centers of the Northern Rockies - Billings
  - Billings, Montana, Forenede Stater, 59101
    - Northern Rockies Radiation Oncology Center
  - Billings, Montana, Forenede Stater, 59101
    - St. Vincent Healthcare Cancer Care Services
  - Billings, Montana, Forenede Stater, 59107-7000
    - Billings Clinic - Downtown
  - Bozeman, Montana, Forenede Stater, 59715
    - Bozeman Deaconess Cancer Center
  - Butte, Montana, Forenede Stater, 59701
    - St. James Healthcare Cancer Care
  - Great Falls, Montana, Forenede Stater, 59405
    - Great Falls Clinic - Main Facility
  - Great Falls, Montana, Forenede Stater, 59405
  - Helena, Montana, Forenede Stater, 59601
    - St. Peter's Hospital
  - Kalispell, Montana, Forenede Stater, 59901
    - Kalispell Regional Medical Center
  - Kalispell, Montana, Forenede Stater, 59901
    - Glacier Oncology, PLLC
  - Kalispell, Montana, Forenede Stater, 59901
    - Kalispell Medical Oncology at KRMC
  - Missoula, Montana, Forenede Stater, 59801
    - Community Medical Center
  - Missoula, Montana, Forenede Stater, 59804
    - Guardian Oncology and Center for Wellness
  - Missoula, Montana, Forenede Stater, 59807-7877
    - Montana Cancer Specialists at Montana Cancer Center
  - Missoula, Montana, Forenede Stater, 59807
    - Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
- North Carolina
  - Rutherfordton, North Carolina, Forenede Stater, 28139
    - Rutherford Hospital
- North Dakota
  - Bismarck, North Dakota, Forenede Stater, 58501
    - Bismarck Cancer Center
  - Bismarck, North Dakota, Forenede Stater, 58501
    - Medcenter One Hospital Cancer Care Center
  - Bismarck, North Dakota, Forenede Stater, 58501
    - Mid Dakota Clinic, PC
  - Bismarck, North Dakota, Forenede Stater, 58502
    - St. Alexius Medical Center Cancer Center
  - Fargo, North Dakota, Forenede Stater, 58122
    - CCOP - MeritCare Hospital
  - Fargo, North Dakota, Forenede Stater, 58122
    - MeritCare Broadway
- Ohio
  - Bellefontaine, Ohio, Forenede Stater, 43311
    - Mary Rutan Hospital
  - Bowling Green, Ohio, Forenede Stater, 43402
    - Wood County Oncology Center
  - Chillicothe, Ohio, Forenede Stater, 45601
    - Adena Regional Medical Center
  - Columbus, Ohio, Forenede Stater, 43214-3998
    - Riverside Methodist Hospital Cancer Care
  - Columbus, Ohio, Forenede Stater, 43222
    - Mount Carmel Health - West Hospital
  - Columbus, Ohio, Forenede Stater, 43215
    - CCOP - Columbus
  - Columbus, Ohio, Forenede Stater, 43215
    - Grant Medical Center Cancer Care
  - Columbus, Ohio, Forenede Stater, 43228
    - Doctors Hospital at Ohio Health
  - Dayton, Ohio, Forenede Stater, 45405
    - Grandview Hospital
  - Dayton, Ohio, Forenede Stater, 45406
    - Good Samaritan Hospital
  - Dayton, Ohio, Forenede Stater, 45415
    - Samaritan North Cancer Care Center
  - Dayton, Ohio, Forenede Stater, 45429
    - CCOP - Dayton
  - Delaware, Ohio, Forenede Stater, 43015
    - Grady Memorial Hospital
  - Elyria, Ohio, Forenede Stater, 44035
    - Hematology Oncology Center
  - Findlay, Ohio, Forenede Stater, 45840
    - Blanchard Valley Medical Associates
  - Franklin, Ohio, Forenede Stater, 45005-1066
    - Middletown Regional Hospital
  - Kettering, Ohio, Forenede Stater, 45429
    - Charles F. Kettering Memorial Hospital
  - Lancaster, Ohio, Forenede Stater, 43130
    - Fairfield Medical Center
  - Lima, Ohio, Forenede Stater, 45804
    - Lima Memorial Hospital
  - Marietta, Ohio, Forenede Stater, 45750
    - Strecker Cancer Center at Marietta Memorial Hospital
  - Maumee, Ohio, Forenede Stater, 43537
    - Northwest Ohio Oncology Center
  - Maumee, Ohio, Forenede Stater, 43537
    - St. Luke's Hospital
  - Newark, Ohio, Forenede Stater, 43055
    - Licking Memorial Cancer Care Program at Licking Memorial Hospital
  - Oregon, Ohio, Forenede Stater, 43616
    - St. Charles Mercy Hospital
  - Oregon, Ohio, Forenede Stater, 43616
    - Toledo Clinic - Oregon
  - Sandusky, Ohio, Forenede Stater, 44870
    - Firelands Regional Medical Center
  - Sandusky, Ohio, Forenede Stater, 44870
    - North Coast Cancer Care, Incorporated
  - Springfield, Ohio, Forenede Stater, 45505
    - Community Hospital of Springfield and Clark County
  - Springfield, Ohio, Forenede Stater, 45504
    - Mercy Medical Center
  - Sylvania, Ohio, Forenede Stater, 43560
    - Flower Hospital Cancer Center
  - Tiffin, Ohio, Forenede Stater, 44883
    - Mercy Hospital of Tiffin
  - Toledo, Ohio, Forenede Stater, 43608
    - St. Vincent Mercy Medical Center
  - Toledo, Ohio, Forenede Stater, 43606
    - Toledo Hospital
  - Toledo, Ohio, Forenede Stater, 43614
    - Medical University of Ohio Cancer Center
  - Toledo, Ohio, Forenede Stater, 43617
    - CCOP - Toledo Community Hospital
  - Toledo, Ohio, Forenede Stater, 43623
    - Toledo Clinic, Incorporated - Main Clinic
  - Troy, Ohio, Forenede Stater, 45373-1300
    - UVMC Cancer Care Center at Upper Valley Medical Center
  - Wauseon, Ohio, Forenede Stater, 43567
    - Fulton County Health Center
  - Westerville, Ohio, Forenede Stater, 43081
    - Mount Carmel St. Ann's Cancer Center
  - Wilmington, Ohio, Forenede Stater, 45177
    - Clinton Memorial Hospital
  - Xenia, Ohio, Forenede Stater, 45385
    - Ruth G. McMillan Cancer Center at Greene Memorial Hospital
  - Zanesville, Ohio, Forenede Stater, 43701
    - Genesis - Good Samaritan Hospital
- Oklahoma
  - Tulsa, Oklahoma, Forenede Stater, 74136
    - Natalie Warren Bryant Cancer Center at St. Francis Hospital
- Pennsylvania
  - Danville, Pennsylvania, Forenede Stater, 17822-0001
    - Geisinger Cancer Institute at Geisinger Health
  - Hazleton, Pennsylvania, Forenede Stater, 18201
    - Geisinger Hazleton Cancer Center
  - State College, Pennsylvania, Forenede Stater, 16801
    - Geisinger Medical Group - Scenery Park
  - Wilkes-Barre, Pennsylvania, Forenede Stater, 18711
    - Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
  - Wilkes-Barre, Pennsylvania, Forenede Stater, 18765
    - Mercy Hospital at Wilkes-Barre
- South Carolina
  - Anderson, South Carolina, Forenede Stater, 29621
    - AnMed Cancer Center
  - Spartanburg, South Carolina, Forenede Stater, 29303
    - CCOP - Upstate Carolina
  - Spartanburg, South Carolina, Forenede Stater, 29303
    - Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
- South Dakota
  - Rapid City, South Dakota, Forenede Stater, 57701
    - Rapid City Regional Hospital
  - Sioux Falls, South Dakota, Forenede Stater, 57105
    - Avera Cancer Institute
  - Sioux Falls, South Dakota, Forenede Stater, 57105
    - Medical X-Ray Center, PC
  - Sioux Falls, South Dakota, Forenede Stater, 57117-5039
    - Sanford Cancer Center at Sanford USD Medical Center
- Virginia
  - Fredericksburg, Virginia, Forenede Stater, 22401
    - Fredericksburg Oncology, Incorporated
- Washington
  - Kirkland, Washington, Forenede Stater, 98033
    - Cascade Cancer Center at Evergreen Hospital Medical Center
  - Port Angeles, Washington, Forenede Stater, 98362
    - Olympic Medical Center
  - Renton, Washington, Forenede Stater, 98055
    - Southlake Clinic
  - Seattle, Washington, Forenede Stater, 98101
    - Virginia Mason Medical Center
  - Seattle, Washington, Forenede Stater, 98101
    - CCOP - Virginia Mason Research Center
- Wyoming
  - Sheridan, Wyoming, Forenede Stater, 82801
    - Welch Cancer Center at Sheridan Memorial Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Postmenopausal women with breast cancer.

Beskrivelse

DISEASE CHARACTERISTICS:

Inclusion criteria:

Must have histologically confirmed invasive breast cancer, as defined by the following TNM staging criteria:
- pT1, pT2, or pT3
- pNx, pN0, pN1, pN2, or pN3*
  - Patients with positive sentinel node biopsies (pN1) must have subsequent axillary dissection to be eligible
  - Patients with negative sentinel node biopsies (pN0) do not require axillary surgery for study eligibility
- M0, according to the following radiologic studies:
  - Bone scan (required only if alkaline phosphatase is > 2 x institutional upper limit of normal [ULN] and/or there are symptoms of metastatic disease)
    - A confirmatory x-ray or other imaging study, such as CT scan or MRI, is required if the results from the bone scan are questionable
  - Abdominal ultrasound or CT scan of the abdomen (required only if AST/ALT or alkaline phosphatase is > 2 x ULN unless the elevation is in the bone fraction)
  - Chest x-ray NOTE: *Only when the sole basis for this classification is the presence of 10 or more involved axillary nodes
Completely resected disease
- Surgical margins must be clear of invasive carcinoma and ductal carcinoma in situ or lobular carcinoma in situ
Must have one intact, noncancerous breast with no history of previous breast surgery in that breast (other than a breast biopsy)
- Mammogram of the intact, noncancerous breast required ≤ 6 months prior to study registration (both a craniocaudal [top down] and mediolateral oblique view [side view] must be available)
Must be registered on this study ≥ 3 weeks but ≤ 3 months after completion of chemotherapy OR primary surgery*
- Adjuvant chemotherapy and radiation therapy as prescribed by the local institution is allowed provided patient is registered on this study and hormonal treatment is begun as soon as patient has sufficiently recovered from chemotherapy NOTE: *Primary surgery is defined as the last surgical procedure to remove invasive or in situ disease
Planning to receive anastrozole or exemestane for ≥ 1 year for treatment of breast cancer
Hormone receptor status:
- Estrogen receptor- and/or progesterone receptor-positive (defined as a tumor receptor content of > 10 fmol/mg protein OR receptor-positive by immunohistochemistry [ERICA or PgRICA])

PATIENT CHARACTERISTICS:

Inclusion criteria:

Female
Postmenopausal, defined by one of the following:
- Age > 60 years
- Age 45-59 years with spontaneous cessation of menses > 12 months prior to chemotherapy (if no chemotherapy was given, then prior to study registration)
- Age 45-59 years with cessation of menses for a duration of < 12 months or secondary to hysterectomy AND an FSH level in the postmenopausal range (or ≥ 34.4 IU/L, if institutional range is not available) prior to chemotherapy (if no chemotherapy was given, then prior to study registration)
- Age 45-59 years with an FSH level in the postmenopausal range according to institutional laboratory standards (or > 34.4 IU/L, if the institutional range is not available) prior to chemotherapy (if no chemotherapy was given, then prior to study registration)
- Bilateral oophorectomy
ECOG performance status 0, 1, or 2
Life expectancy ≥ 5 years

Exclusion criteria:

History of other (non-breast) malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, or other curatively treated solid tumors with no evidence of disease for > 5 years
Any co-existing medical or psychiatric condition that is likely to interfere with study procedures and/or results

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

See Disease Characteristics

Exclusion criteria:

Hormone replacement therapy, oral contraceptives, tamoxifen, raloxifene, other selective estrogen-receptor modulators, or gonadotropin releasing-hormone analogues ≤ 6 months prior to the pre-registration mammogram
Prior treatment with an aromatase inhibitor (e.g., anastrozole, exemestane, letrozole)
Planned surgery (other than core needle biopsy) to intact non-cancerous breast (e.g., preventive/prophylactic mastectomy)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Antal grupper/kohorter

Kohorter og interventioner

Gruppe / kohorte	Intervention / Behandling
Group 1 Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined. Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy.	Genetisk: polymorfi analyse Andet: laboratoriebiomarkøranalyse Andet: højtydende væskekromatografi Procedure: radiomammografi

Gruppe / kohorte

Intervention / Behandling

Group 1

Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy.

Genetisk: polymorfi analyse

Andet: laboratoriebiomarkøranalyse

Andet: højtydende væskekromatografi

Procedure: radiomammografi

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål	Tidsramme
Changes in percent breast density in response to 1 year of aromatase inhibitor therapy Tidsramme: Up to 12 months	Up to 12 months
Changes in dense area in response to 1 year of aromatase inhibitor therapy Tidsramme: Up to 12 months	Up to 12 months
Correlation of changes in percent breast density with changes in plasma hormone levels and drug levels Tidsramme: Up to 12 months	Up to 12 months
Correlation of changes in dense area with changes in plasma hormone levels and drug levels Tidsramme: Up to 12 months	Up to 12 months
Comparison of percent breast density in women with high pre-treatment percent density vs women with low pre-treatment percent density Tidsramme: Up to 12 months	Up to 12 months
Comparison of dense area in women with high pre-treatment dense area vs women with low pre-treatment dense area Tidsramme: Up to 12 months	Up to 12 months
Associations of haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway with changes in percent and area density, plasma hormone levels, and drug levels after 1 year of aromatase inhibitor therapy Tidsramme: Up to 12 months	Up to 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Alliance for Clinical Trials in Oncology

Samarbejdspartnere

National Cancer Institute (NCI)

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2007

Primær færdiggørelse (Faktiske)

1. december 2009

Studieafslutning (Faktiske)

1. december 2009

Datoer for studieregistrering

Først indsendt

14. august 2007

Først indsendt, der opfyldte QC-kriterier

14. august 2007

Først opslået (Skøn)

15. august 2007

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

13. juli 2016

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. juli 2016

Sidst verificeret

1. juli 2016

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

NCCTG-N063I
NCI-2012-02719 (Registry Identifier: CTRP (Clinical Trials Reporting System))
CDR0000560200 (Registry Identifier: PDQ (Physician Data Query))

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Brystkræft

Cairo University

Ikke rekrutterer endnu

Gyldighed og pålidelighed af arabisk version af brystspørgeskema

BREAST-Q
The First Affiliated Hospital of Xiamen University

Ikke rekrutterer endnu

Pyrotinib maleat -tabletter i kombination med dalpiciclib isethionate tabletter og standard endokrin terapi

Locally Advanced Breast Cancer (LABC)
Abouqir General Hospital
Alexandria University

Rekruttering

Øjeblikkelig brystrekonstruktion med hybrid fedtoverførsel

Breast Udseende Rekonstruktion Disproportion

Egypten
Beijing Bio-Targeting Therapeutics Technology Co...

Trukket tilbage

En klinisk undersøgelse for at undersøge sikkerheden, tolerabiliteten og effektiviteten af rekombinant human NSIL12 Oncolytisk adenovirusinjektion (BIOTTT001) kombineret med neoadjuvansbehandling til lokalt avanceret brystkræft

Locally Advanced Breast Cancer (LABC)

Kina
Indonesia University

Ikke rekrutterer endnu

Præoperative skulderøvelser og postoperativ inflammation, smerte og funktion efter modificeret radikal mastektomi

Præhabilitering | Postoperativ inflammation | Locally Advanced Breast Cancer (LABC)

Indonesien
Tianjin Medical University Cancer Institute and...
Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnere

Afsluttet

De tekniske operationer og standard klinisk anvendelsesprotokol for CBBCT i diagnostisk proces af brystkræft (CBBCT)

Den kliniske anvendelsesvejledning af Conebeam Breast CT

Kina
Atlas University

Ikke rekrutterer endnu

Patient-afledte organoider til funktionel karakterisering af kemoterapiresistens i brystkræft (BC-PDO)

Brystkræft | Locally Advanced Breast Cancer (LABC)

Tyrkiet (Türkiye)
ETOP IBCSG Partners Foundation

Afsluttet

Forsøg om den endokrine aktivitet af Neoadjuvant Degarelix (TREND)

Breast Cancer Invasive Nos

Italien
Spanish Breast Cancer Research Group
Hoffmann-La Roche; Roche Farma, S.A

Afsluttet

A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer

Breast Cancer Invasive Nos

Spanien
Second Affiliated Hospital, School of Medicine,...

Rekruttering

Neoadjuvant Toripalimab plus SBRT til kemoresistent triple-negativ brystkræft (NEOTRIO-2)

TNBC, Triple Negative Breast Cancer

Kina

Kliniske forsøg med polymorfi analyse

Centre Médico-Chirurgical de Réadaptation des Massues...

Rekruttering

Karakterisering af synsopfattelsesforstyrrelser hos patienter med idiopatisk skoliose (EYAIS)

Idiopatisk skoliose

Frankrig
Liao Jian An

Rekruttering

Meridianenergiændringer hos patienter med hoved- og nakkekræft efter kemoterapi eller strålebehandling

Hoved- og halskræft

Taiwan
Nantes University Hospital

Ikke rekrutterer endnu

Reproducerbarhed af dental bidmærkeoverlayanalyse ved hjælp af digitale 3D-modeller hos voksne deltagere (OVERLAY-REPRO)

Rettsmedicinsk Tandlægevidenskab | Bidanalyse
Fondation Lenval

Trukket tilbage

Indflydelse af træthed på gangmønsteret hos patienter med cerebral parese.

Cerebral Parese

Frankrig
IRCCS Eugenio Medea

Rekruttering

Bekræft præstationen i klinisk praksis af den fordybende Virtual Reality Platform GRAIL (Gait Real-time Analysis Interactive Lab)

Cerebral Parese | Erhvervet hjerneskade

Italien
IRCCS Eugenio Medea

Afsluttet

Biomarkørers baner for tidlig intervention hos søskende til børn med autismespektrumforstyrrelse

Autismespektrumforstyrrelse | Tidlig indsats

Italien
Oregon Health and Science University
4DMedical

Tilmelding efter invitation

Ventilationsubalancer ved let til moderat kronisk obstruktiv lungesygdom (VAPOR)

Lungesygdomme | KOL | Luftvejssygdom | Dyspnø

Forenede Stater
Healthy.io Ltd.

Afsluttet

[Prøvning af enhed, der ikke er godkendt eller godkendt af U.S. FDA]

Albuminuri

Forenede Stater
Medwave Estudios Limitada
Asociación Chilena de Seguridad

Ukendt

Diagnostisk værdi af arbejdsbelastningsanalyseinstrument til at påvise erhvervsmæssige risici ved muskel- og skelettilstande i øvre lemmer (ACT-ACHS)

Erhvervsmæssig eksponering | Muskuloskeletal sygdom

Chile
Fundacion Clinic per a la Recerca Biomédica
Hospital Clinic of Barcelona

Rekruttering

Præcisionsmedicin til L/GCMN og melanom 1 (Precis-mel 1)

Nevi og melanomer | Melanom (hudkræft)

Spanien

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy

Studieoversigt

Status

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Undersøgelsestype

Tilmelding (Faktiske)

Kontakter og lokationer

Studiesteder

Deltagelseskriterier

Berettigelseskriterier

Aldre berettiget til at studere

Tager imod sunde frivillige

Køn, der er berettiget til at studere

Prøveudtagningsmetode

Studiebefolkning

Beskrivelse

Studieplan

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Antal grupper/kohorter

Kohorter og interventioner

Gruppe / kohorte

Intervention / Behandling

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål

Tidsramme

Samarbejdspartnere og efterforskere

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Studer store datoer

Studiestart

Primær færdiggørelse (Faktiske)

Studieafslutning (Faktiske)

Datoer for studieregistrering

Først indsendt

Først indsendt, der opfyldte QC-kriterier

Først opslået (Skøn)

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Sidst verificeret

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

Kliniske forsøg med Brystkræft

Kliniske forsøg med polymorfi analyse

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Guinea

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer